91 Milton Park
Trevor Nicholls, CEO
Oxagen Ltd. is a genomics company that performs large-scale genetic analysis on collections of family samples to understand the mechanisms and causes of common diseases. Its discovery platform includes genome scanning, gene discovery, SNP analysis, functional validation and bioinformatics technologies.
Oxagen’s proprietary collections of family samples and data provide a resource with which to identify and validate the genes causing disease. Its products are information and patents relating to new drug targets or diagnostic markers, which will enable better treatment of diseases.
Oxagen is studying the genetic basis of nine common diseases in three major therapeutic areas: cardiovascular disease, inflammatory disease and metabolic/endocrine disorders. The diseases include coronary artery disease, Type II diabetes, endometriosis, polycystic ovarian syndrome, autoimmune thyroid disease, osteoporosis, inflammatory bowel disease, psoriasis and asthma. The company has partnered its cardiovascular program with AstraZeneca plc.
Collaboration to validate a specified number of gene targets for Oxagen: Cureon A/S.
Research collaboration to investigate the genetics of endometriosis: Cerylid Biosciences Ltd.
Research collaboration to investigate the genetics of osteoporosis: Incyte Genomics Inc.
Technology partners include Genomica Corp., Lynx Therapeutics Inc., Paradigm Therapeutics Ltd., PE Biosystems and Amersham Pharmacia Biotech KK.